Please login to the form below

Not currently logged in

Roche's Julie Warner joins Boyds

She takes up appointment as an associate director at the drug development consultancy

edit-Julie-Warner-Boyds-0914UK-based drug development consultancy Boyds has appointed Julie Warner as associate director within its regulatory affairs team.

She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

The firm hopes Warner's ten years of experience in EU and US regulatory affairs will further strengthen the team, where she will work closely with Robin Henderson, director of regulatory affairs.

Commenting on her new position, Warner said: “The team has an enviable reputation for its long-standing, trusted relationships with regulatory authorities. I look forward to adding to the depth of experience at Boyds and working with clients to provide the regulatory affairs support needed to facilitate the fast and efficient development of their products."

Alan Boyd, CEO and founder of Boyds, said: “Dr Warner's appointment is excellent news for Boyds. Julie brings a wealth of expertise as well as a special interest in orphan drugs and will be a welcome addition to the team.

"I am proud of our reputation for regulatory affairs support. Clients appreciate our ability to not only provide strategic input, but also assistance in the preparation of regulatory documentation to support their activities and guidance through the sometimes complex procedures to help bring their product to the market place."

Warner is also a member of the editorial panel for the professional journal of The Organisation for Professionals in Regulatory Affairs (TOPRA), the Regulatory Rapporteur.

24th September 2014

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?